Panacea Biotec (BOM:531349) ROCE %: -0.02% (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

BOM:531349 Panacea Biotec Ltd BOM:531349
54 GF Score
Price ₹538.20
GF Value ₹359.92
Valuation Significantly Overvalued
! 3 Warning Signs
View Full Analysis

What is Panacea Biotec ROCE %?

Panacea Biotec BOM:531349 +0.09% 54 ROCE % is -0.02% as of Mar. 2026. GuruFocus rates BOM:531349 with a GF Score™ of 54/100 and a GF Value™ of ₹359.92 (Significantly Overvalued). The stock has 3 warning signs investors should review.

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Panacea Biotec's annualized ROCE % for the quarter that ended in Mar. 2026 was -0.02%.

Panacea Biotec  (BOM:531349) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Panacea Biotec ROCE % Related Terms

Panacea Biotec ROCE % Historical Data

* Premium members only.

The historical data trend for Panacea Biotec's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Panacea Biotec ROCE % Chart

Panacea Biotec Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
ROCE %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 190.44 1.73 0.44 -0.44 -0.14

Panacea Biotec Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
ROCE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.43 3.22 -7.49 3.67 -0.02
BOM:531349
54GF Score
Panacea Biotec Ltd BOM:531349
ROCE % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Panacea Biotec ROCE % Calculation

Panacea Biotec's annualized ROCE % for the fiscal year that ended in Mar. 2026 is calculated as:

ROCE %=EBIT/( (Capital Employed+Capital Employed)/ count )
(A: Mar. 2026 )  (A: Mar. 2025 )(A: Mar. 2026 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(A: Mar. 2026 )  (A: Mar. 2025 )(A: Mar. 2026 )
=-13.2/( ( (12897.46 - 3669.93) + (12621.7 - 3486.8) )/ 2 )
=-13.2/( (9227.53+9134.9)/ 2 )
=-13.2/9181.215
=-0.14 %

Panacea Biotec's ROCE % of for the quarter that ended in Mar. 2026 is calculated as:

ROCE %=EBIT (1)/( (Capital Employed+Capital Employed)/ count )
(Q: Mar. 2026 )  (Q: Dec. 2025 )(Q: Mar. 2026 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(Q: Mar. 2026 )  (Q: Dec. 2025 )(Q: Mar. 2026 )
=-2/( ( (0 - 0) + (12621.7 - 3486.8) )/ 1 )
=-2/( ( 0 + 9134.9 )/ 1 )
=-2/9134.9
=-0.02 %

(1) Note: The EBIT data used here is four times the quarterly (Mar. 2026) EBIT data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about ROCE % →
What does a ROCE % of -0.02% mean?
Panacea Biotec (BOM:531349) has a ROCE % of -0.02% as of Mar. 2026.
Is Panacea Biotec's ROCE % too high?
Panacea Biotec's current ROCE % is -0.02%. Overall, Panacea Biotec has a GF Score™ of 54/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Panacea Biotec's ROCE % compare to VRTX and REGN?
Panacea Biotec's ROCE % of -0.02% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROCE % for a Biotechnology company?
A good ROCE % depends on the Biotechnology industry context. However, ROCE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROCE % mean?
A high ROCE % can signal that a stock is expensive relative to its fundamentals. Panacea Biotec's current ROCE % is -0.02%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Panacea Biotec stock overvalued right now?
Based on GuruFocus' analysis, Panacea Biotec (BOM:531349) is currently considered Significantly Overvalued. The stock's GF Value™ is ₹359.92, compared to a current price of ₹538.20 — trading 49.5% above its estimated fair value. The current ROCE % is -0.02%. Panacea Biotec's overall GF Score™ is 54/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROCE % calculated?
ROCE % is calculated from a company's financial statements. For Panacea Biotec (BOM:531349), the current ROCE % is -0.02% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Panacea Biotec (BOM:531349) Overvalued in 2026?

Based on GuruFocus' analysis, Panacea Biotec stock appears to be overvalued. The current stock price of ₹538.20 is trading 49.5% above its estimated GF Value™ of ₹359.92. GuruFocus considers Panacea Biotec to be Significantly Overvalued.

Key valuation signals for BOM:531349:

  • ROCE %: -0.02%
  • GF Value™: ₹359.92 vs. price of ₹538.20 (49.5% above fair value)
  • GF Score™: 54/100 with 3 warning signs

No single metric tells the full story. See the BOM:531349 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Panacea Biotec Business Description

Other Exchanges PANACEABIO:India
Address Mathura Road, B-1 Extension/G-3, Mohan Co-operative Industrial Estate, New Delhi, IND, 110044
Panacea Biotec Ltd is a Biotechnology company. It is engaged in the business of research, development, manufacturing, and marketing of branded pharmaceutical formulations, vaccines, and biopharmaceuticals. The company's operating segments include Vaccines, and Formulations. It generates maximum revenue from the Vaccines segment. The company product portfolio includes prescription products in niche therapeutic areas such as diabetes and cardiovascular management, oncology, nephrology and transplant management, osteoporosis management, gastro-intestinal care, pain management products, and pediatric immunization. The group has a business presence in India and Outside India.
54GF Score

Get the complete analysis for BOM:531349

ROCE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹538.20
Price
₹359.92
GF Value